We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Selexis SA and KBI Biopharma, both JSR Life Sciences companies, have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company focused on T cell redirecting cancer immunotherapies.